Phase 3
Completed N=34
Metformin for the Prevention of Episodic Migraine (MPEM)
Source: ClinicalTrials.gov NCT02593097 ↗Enrolled (actual)
34
Serious AEs
0.0%
Results posted
Jul 2020
Primary outcomePrimary: Headache Days — 23.64; 24.33 Days — p=0.83
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The investigators will evaluate the safety and efficacy of metformin for preventive treatment of migraine in a randomized, double-blind, placebo-controlled, crossover trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Headache Days |
23.64; 24.33 | 0.83 |
| SECONDARY Greater Than >50% Reduction in Migraine Days on Metformin |
10.1 | 0.16 |
| SECONDARY Adverse Events |
3; 1 | — |
Eligibility Criteria
Inclusion Criteria
- age 18-65 years
- a diagnosis of migraine with or without aura for >1 year according to the International Classification of Headache Disorders-IIIb
Exclusion Criteria
- a diagnosis of diabetes mellitus or polycystic ovarian syndrome
- overuse of acute migraine treatments
- failure to respond to 3 or more classes of preventive drug treatments
- change in dose of migraine-preventive medication within 2 months of beginning the baseline diary phase
- significant somatic or psychiatric disease
- known alcohol or other substance abuse
- pregnant or breastfeeding.
Data sourced from ClinicalTrials.gov (NCT02593097). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.